Dermata Therapeutics Company Insiders
| DRMAW Stock | USD 0.02 0 20.50% |
Dermata Therapeutics employs about 8 people. The company is managed by 7 executives with a total tenure of roughly 19 years, averaging almost 2.0 years of service per executive, having 1.14 employees per reported executive. Recap of Dermata Therapeutics' management performance can provide insight into the venture performance.
Dermata |
Dermata Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (1.3587) % which means that it has lost $1.3587 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (3.1044) %, meaning that it generated substantial loss on money invested by shareholders. Dermata Therapeutics' management efficiency ratios could be used to measure how well Dermata Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -3.65 in 2025. Return On Capital Employed is likely to drop to -3.72 in 2025. At this time, Dermata Therapeutics' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to climb to about 3.3 B in 2025, whereas Non Currrent Assets Other are likely to drop slightly above 44.6 K in 2025.Common Stock Shares Outstanding is likely to climb to about 1.6 M in 2025
Dermata Therapeutics Workforce Comparison
Dermata Therapeutics Warrant is rated # 5 in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 46.0. Dermata Therapeutics retains roughly 8.0 in number of employees claiming about 17% of equities under Health Care industry.
Dermata Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Dermata Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Dermata Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Dermata Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
David Hale over six months ago Acquisition by David Hale of 10000 shares of Dermata Therapeutics at 0.6099 subject to Rule 16b-3 | ||
Fisher Mary over six months ago Acquisition by Fisher Mary of 5000 shares of Dermata Therapeutics at 1.88 subject to Rule 16b-3 | ||
Sandler Andrew Seth over six months ago Acquisition by Sandler Andrew Seth of 10000 shares of Dermata Therapeutics at 0.6099 subject to Rule 16b-3 | ||
Bedoya-toro Munera Maria E over six months ago Acquisition by Bedoya-toro Munera Maria E of 15000 shares of Dermata Therapeutics at 1.88 subject to Rule 16b-3 |
Dermata Therapeutics Notable Stakeholders
A Dermata Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Dermata Therapeutics often face trade-offs trying to please all of them. Dermata Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Dermata Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| David Hale | CoFounder Director | Profile | |
| Mr MPH | VP Devel | Profile | |
| Maria MBA | Senior Assurance | Profile | |
| Gerald Proehl | Chairman, CoFounder | Profile | |
| Kyri Hoose | VP CFO | Profile | |
| Sean Proehl | Senior Development | Profile | |
| Dr MPH | Senior Officer | Profile |
About Dermata Therapeutics Management Performance
The success or failure of an entity such as Dermata Therapeutics often depends on how effective the management is. Dermata Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Dermata management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Dermata management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (3.48) | (3.65) | |
| Return On Capital Employed | (3.54) | (3.72) | |
| Return On Assets | (3.48) | (3.65) | |
| Return On Equity | (7.87) | (7.48) |
Please note, the imprecision that can be found in Dermata Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Dermata Therapeutics Warrant. Check Dermata Therapeutics' Beneish M Score to see the likelihood of Dermata Therapeutics' management manipulating its earnings.
Dermata Therapeutics Workforce Analysis
Traditionally, organizations such as Dermata Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Dermata Therapeutics within its industry.Dermata Therapeutics Manpower Efficiency
Return on Dermata Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.5B | |
| Net Loss Per Executive | 1.8B | |
| Working Capital Per Employee | 195.1K | |
| Working Capital Per Executive | 223K |
Additional Tools for Dermata Stock Analysis
When running Dermata Therapeutics' price analysis, check to measure Dermata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermata Therapeutics is operating at the current time. Most of Dermata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dermata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermata Therapeutics' price. Additionally, you may evaluate how the addition of Dermata Therapeutics to your portfolios can decrease your overall portfolio volatility.